It is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.
Rob Besse
Advertisement
Rob Besse is Vice President, Archbow Consulting.
Articles by Rob Besse
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A
2
FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
3
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
4
Additive Manufacturing's Application in Pharma and Biotech
5